Last $1.66 USD
Change Today +0.01 / 0.61%
Volume 68.0K
CTIX On Other Exchanges
As of 5:20 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

cellceutix corp (CTIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/13 - $2.32
52 Week Low
12/4/13 - $1.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLCEUTIX CORP (CTIX)

Related News

No related news articles were found.

cellceutix corp (CTIX) Related Businessweek News

No Related Businessweek News Found

cellceutix corp (CTIX) Details

Cellceutix Corporation, a clinical stage biopharmaceutical company, focuses on discovering and developing small molecule drugs to treat drug-resistant cancers, psoriasis, autism, and inflammatory diseases. Its flagship compound includes Kevetrin, an anti-cancer compound that is in Phase I clinical trials for the treatment of cancer. The company’s preclinical stage compounds comprise KM 133 for the treatment of psoriasis; KM 391 for the treatment of autism; KM 277 for the treatment of arthritis; and KM 278 for the treatment of arthritis/asthma. Its early stage research and development products include KM 362 for the treatment of MS/ALS/Parkinson’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency. The company also offers Brilacidin, an antibiotic to treat various indications, including ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS caused by drug-sensitive or drug-resistant strains of Staphylococcus aureus bacteria; oral mucositis, an oral rinse containing brilacidin; and Delparantag, a synthetic small-molecule. In addition, it provides compounds active against gram-negative bacteria, fungal infections, malaria, tuberculosis, biowarfare pathogens, and PolyCide antimicrobial biomaterials. The company was founded in 2007 and is headquartered in Beverly, Massachusetts.

9 Employees
Last Reported Date: 09/30/13
Founded in 2007

cellceutix corp (CTIX) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: $404.3K
President, Chief Scientific Officer and Direc...
Total Annual Compensation: $404.3K
Compensation as of Fiscal Year 2013.

cellceutix corp (CTIX) Key Developments

Cellceutix Corporation Announces Significant Breakthrough in the Formulation of Brilacidin

Cellceutix Corporation announced that a significant breakthrough has been made in the formulation of Brilacidin, the company's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications.

Cellceutix's Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board

Cellceutix announced another important milestone in the development of Brilacidin(TM), the lead compound in a novel class of antibiotics known as defensin-mimetics. In the company's phase 2b study on patients with acute bacterial skin and skin structure infections (ABSSSI), an independent Data Safety Monitoring Board (DSMB) gave a positive review of interim safety data, collected after approximately 50% of the subjects were enrolled. The DSMB is composed of two cardiologists, one neurologist, and one statistician, and its mandate is to monitor and promote the safety of study participants. The DSMB recommended that Cellceutix continue the trial as planned. That is the best possible outcome. Independent experts did not observe any concerning safety signals in the study. In addition, the Company reports there are no treatment-related Serious Adverse Events (SAEs), and none classified as cardiovascular or neurological, thus far in the study. Previous brilacidin phase 1 and 2 studies have indicated the drug is safe and effective in the treatment of ABSSSI caused by Staph aureus, including methicillin-resistant Staph aureus (MRSA). Any treatment-related adverse events in past trials were more likely due to a higher total dose of study drug. However, in the current study, brilacidin is given as a single-dose regimen in two treatment arms (0.6 or 0.8 mg/kg), and in the third arm, it is given as a 3-day regimen, which represents the high amount a subject could receive (total 1.2 mg/kg).

Cellceutix Corporation Reports the Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort

Cellceutix Corporation reported that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing was been increased approximately 33% from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly. The enrollment in the Phase 2b clinical trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is approximately 70% complete.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIX:US $1.66 USD +0.01

CTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CTIX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 194.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLCEUTIX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at